Pfizer Receives FDA Approval for Retevmo in RET Fusion-Positive NSCLC

Pfizer today announced that the FDA has approved Retevmo (selpercatinib) for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC). In the Phase 3 LIBRETTO-431 trial, Retevmo demonstrated a statistically significant improvement in progression-free survival compared to platinum-based chemotherapy with or without pembrolizumab. The median PFS was 24.8 months for Retevmo versus 11.2 months for the comparator. Retevmo is a highly selective RET kinase inhibitor. This approval establishes Retevmo as the preferred first-line treatment for patients with RET fusion-positive NSCLC.